Johnson & Johnson: The Unsinkable

I had a quick exchange about Johnson & Johnson (NYSE:JNJ) with a few investors who pointed out on Tuesday that it appeared evident that the bears who had previously talked of a stock grossly overvalued at just over $110 did not know what they were talking about earlier this year.

Now changing hands at about $140 in pre-market, the stock is valued at about 23x forward earnings, 14.5x forward EV/Ebitda, 5x forward EV/revenues and 5x book value.

(Source: 4-traders.com)

On the one hand, these metrics were supported on Tuesday by a strong trading update, but on the other, they also point to the possibility that something has gone seriously wrong in recent months with regard to the re-pricing of equity risk.

READ FULL ARTICLE HERE